Table 3. Correlation between mRNA score and clinical and laboratory features in CN-AML patients (n = 158).
| Variant | Total | mRNA Score | P | |
|---|---|---|---|---|
| Low (n = 79) | High (n = 79) | |||
| Age* (years) | 58 (16–90) | 55 (18–87) | 62 (16–90) | 0.027 |
| Age, in groups | ||||
| >60 | 76 (48.1%) | 32 (40.5%) | 44 (55.7%) | 0.056 |
| >50 | 97 (61.4%) | 43 (54.4%) | 54 (68.4%) | 0.072 |
| Gender | ||||
| male | 90 (57.0%) | 44 (55.7%) | 46 (58.2%) | 0.748 |
| Lab data* | ||||
| WBC (×103/μL) | 28.88 (0.65–423.0) | 41.38 (0.98–423.0) | 24.72 (0.65–341.4) | 0.042 |
| Blasts (×103/μL) | 13.77 (0–342.1) | 18.69 (0–342.1) | 10.78 (0–310.7) | 0.056 |
| Hemoglobin, g/dL | 8.1 (3.7–14.0) | 8.3 (4.2–14.0) | 7.9 (3.7–13.2) | 0.173 |
| Platelets (×103/μL) | 53.0 (6–331) | 42.0 (6–214) | 60.0 (9–331) | 0.006 |
| LDH (U/L) | 878.0 (274–13130) | 960.0 (354–13130) | 804.0 (274–7177) | 0.053 |
| FAB | 0.156 | |||
| M0 | 2 (1.3%) | 0 | 2 (2.5%) | 0.155 |
| M1 | 37 (23.4%) | 24 (30.4%) | 13 (16.5%) | 0.039 |
| M2 | 53 (33.5%) | 28 (35.4%) | 25 (31.6%) | 0.613 |
| M4 | 52 (32.9%) | 22 (27.8%) | 30 (38.0%) | 0.176 |
| M5 | 12 (7.6%) | 4 (5.1%) | 8 (10.1%) | 0.230 |
| M6 | 2 (1.3%) | 1 (1.3%) | 1 (1.3%) | >0.999 |
*
median (range)